Clinical trial
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer…
NCT00327288 · AmpliMed Corporation, Industry · Completed
Key facts
| NCT number | NCT00327288 |
|---|---|
| Title | Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients |
| Official title | A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Taxotere® (Docetaxel) in Previously Treated Inoperable Stage III and Stage IV Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic Previously Treated Breast Cancer or Hormone Refractory Prostate Cancer |
| Lead sponsor | AmpliMed Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer |
| Intervention type | Drug |
| Interventions | imexon, docetaxel |
| Enrollment | 34 |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | May 18, 2006 |
| Last update posted | Jun 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: